|
|
|
|
| LEADER |
05110nam a22004935i 4500 |
| 001 |
8786 |
| 003 |
DE-He213 |
| 005 |
20130725194311.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2010 xxu| s |||| 0|eng d |
| 020 |
# |
# |
|a 9781441908407
|9 978-1-4419-0840-7
|
| 024 |
7 |
# |
|a 10.1007/978-1-4419-0840-7
|2 doi
|
| 050 |
# |
4 |
|a RM1-950
|
| 072 |
# |
7 |
|a MMG
|2 bicssc
|
| 072 |
# |
7 |
|a MED071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615
|2 23
|
| 100 |
1 |
# |
|a Pang, K. Sandy.
|e editor.
|
| 245 |
1 |
0 |
|a Enzyme- and Transporter-Based Drug-Drug Interactions
|b Progress and Future Challenges /
|c edited by K. Sandy Pang, A. David Rodrigues, Raimund M. Peter.
|h [electronic resource] :
|
| 250 |
# |
# |
|a 1.
|
| 264 |
# |
1 |
|a New York, NY :
|b Springer New York,
|c 2010.
|
| 300 |
# |
# |
|b online resource.
|
| 336 |
# |
# |
|a text
|b txt
|2 rdacontent
|
| 337 |
# |
# |
|a computer
|b c
|2 rdamedia
|
| 338 |
# |
# |
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
# |
# |
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
# |
|a Enzymatic Basis Of Phase I And Phase II Drug Metabolism -- Transporters: Importance In Drug Absorption, Distribution And Elimination -- ADME Pharmacogenetics and Its Impact on Drug-Drug Interactions -- Impact Of Nuclear Receptors, CAR, PXR, FXR, And VDR, And Their Ligands On Enzymes And Transporters -- Impact of Physiological Determinants: Flow, Binding, Transporters And Enzymes On Organ and Total Body Clearances -- In Silico Approaches to Predict Drug-Drug Interactions -- In Vitro Techniques To Study Drug-Drug Interactions Of Drug Metabolism: Cytochrome P450 -- In Vitro Characterization Of Inhibitory Drug-Drug Interactions Involving UDP-Glucuronosyltransferase -- In Vitro Techniques To Study Transporter-Based Drug-Drug Interactions -- In Vitro Techniques To Study Drug-Drug Interactions Involving Transport: Caco-2 Model For Study Of P-Glycoprotein And Other Transporters -- Use Of In Vivo Animal Models To Assess Drug-Drug Interactions -- Extrapolation of In Vitro Metabolic and P-Glycoprotein-mediated Transport Data To In Vivo By Modeling and Simulations -- Translation Of In Vitro Metabolic Data To Predict In Vivo Drug-Drug Interactions: IVIVE And Modeling And Simulations -- Absorption Models To Examine Bioavailability And DDI<U+0019>s In Humans -- Management Of Drug Interactions Of New Drugs In Multicenter Trials Using The Metabolism & Transport Drug Interaction Database♭ -- Web-Based Database As A Tool To Examine Drug-Drug Interactions Involving Transporters -- Drug Disposition And Drug-Drug Interactions: Importance Of First-Pass Metabolism In Gut And Liver -- Transporter Based Drug-Drug Interactions And Their Effect On Distribution Volumes -- Inactivation Of Human Cytochrome P450 Enzymes And Drug-Drug Interactions -- Allosteric Enzyme And Transporter Based Interactions -- Interplay Of Transporter-Drug Interaction: Complications Of Both Inhibitory And Inductive Events In Drug-Drug Interaction -- Herbal Supplement-Based Interactions -- Anticipating And Minimizing Drug Interactions In A Drug Discovery And Development Setting: Industrial Perspective -- Clinical Studies Of Drug-Drug Interactions: Design And Interpretation -- Toxicological Consequences Of Drug-Drug Interactions -- Complex Drug Interactions: Significance And Evaluation -- DDI: Labeling And Marketing Perspectives -- Drug-Drug Interactions: What Have We Learnt And Where Are We Going?.
|
| 520 |
# |
# |
|a This volume is authored by esteemed experts in the field, and provides state-of-the art knowledge related to enzyme- and transporter-based DDIs that impact the absorption and disposition of drugs. It examines the types of DDIs, methodological approaches to evaluate and view DDIs mechanistically, bioinformatics, clinical and toxicological outcomes, and regulatory recommendations. As much as possible, the future challenges and opportunities that lie ahead are presented and discussed. Special emphases are placed on the quantitative assessment of the roles of different transporters, need for more specific probes and inhibitors, and recognition of extrahepatic eliminating organs. Future approaches should integrate transporters and enzymes to accelerate the development of physiological based-pharmacokinetic models (PBPK-DDI) and information related to inter-subject variability. In addition, the authors look beyond small molecules and consider DDIs involving biologic agents, such as therapeutic antibodies, that can bring about pharmacologically significant drug-cytokine or drug-endocrine interactions.
|
| 650 |
# |
0 |
|a Medicine.
|
| 650 |
# |
0 |
|a Toxicology.
|
| 650 |
# |
0 |
|a Analytical biochemistry.
|
| 650 |
# |
0 |
|a Biochemistry.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Analytical Chemistry.
|
| 650 |
2 |
4 |
|a Medicinal Chemistry.
|
| 700 |
1 |
# |
|a Rodrigues, A. David.
|e editor.
|
| 700 |
1 |
# |
|a Peter, Raimund M.
|e editor.
|
| 710 |
2 |
# |
|a SpringerLink (Online service)
|
| 773 |
0 |
# |
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781441908391
|
| 856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-1-4419-0840-7
|
| 912 |
# |
# |
|a ZDB-2-SBL
|
| 950 |
# |
# |
|a Biomedical and Life Sciences (Springer-11642)
|